{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:47:27Z","timestamp":1792928847417,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40273-025-01566-0","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T17:36:05Z","timestamp":1764869765000},"page":"287-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Economic Evaluations of CAR-T Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Systematic Review"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6958-7466","authenticated-orcid":false,"given":"Tien Hoang","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3194-4016","authenticated-orcid":false,"given":"Hyung Seok John","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"1566_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01958-w","volume":"16","author":"A Berhan","year":"2025","unstructured":"Berhan A, Almaw A, Damtie S, Solomon Y. Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review. Discov Oncol. 2025;16:184. https:\/\/doi.org\/10.1007\/s12672-025-01958-w.","journal-title":"Discov Oncol"},{"key":"1566_CR2","unstructured":"Padala SA, Kallam A. Diffuse large B-cell lymphoma. StatPearls. Treasure Island: StatPearls Publishing; 2025."},{"key":"1566_CR3","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/ajh.27075","volume":"98","author":"M Tavakkoli","year":"2023","unstructured":"Tavakkoli M, Barta SK. 2024 update: advances in the risk stratification and management of large B-cell lymphoma. Am J Hematol. 2023;98:1791\u2013805. https:\/\/doi.org\/10.1002\/ajh.27075.","journal-title":"Am J Hematol"},{"key":"1566_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11121345","volume":"11","author":"Y Sawalha","year":"2021","unstructured":"Sawalha Y. Relapsed\/refractory diffuse large B-cell lymphoma: a look at the approved and emerging therapies. J Pers Med. 2021;11:1345. https:\/\/doi.org\/10.3390\/jpm11121345.","journal-title":"J Pers Med"},{"key":"1566_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010070","volume":"13","author":"AM Garc\u00eda-Sancho","year":"2023","unstructured":"Garc\u00eda-Sancho AM, Cabero A, Guti\u00e9rrez NC. Treatment of relapsed or refractory diffuse large B-cell lymphoma: new approved options. J Clin Med. 2023;13:70. https:\/\/doi.org\/10.3390\/jcm13010070.","journal-title":"J Clin Med"},{"key":"1566_CR6","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138. https:\/\/doi.org\/10.1182\/blood-2017-03-769620.","journal-title":"Blood"},{"key":"1566_CR7","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/ejh.14166","volume":"112","author":"N Yamauchi","year":"2024","unstructured":"Yamauchi N, Maruyama D. Current development of chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma and high-grade B-cell lymphoma. Eur J Haematol. 2024;112:662\u201377. https:\/\/doi.org\/10.1111\/ejh.14166.","journal-title":"Eur J Haematol"},{"key":"1566_CR8","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1002\/cam4.3881","volume":"10","author":"G Iacoboni","year":"2021","unstructured":"Iacoboni G, Villacampa G, Martinez-Cibrian N, Bail\u00e9n R, Lopez Corral L, Sanchez JM, et al. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Med. 2021;10:3214\u201323. https:\/\/doi.org\/10.1002\/cam4.3881.","journal-title":"Cancer Med"},{"key":"1566_CR9","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1182\/bloodadvances.2020003848","volume":"5","author":"SS Neelapu","year":"2021","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021;5:4149\u201355. https:\/\/doi.org\/10.1182\/bloodadvances.2020003848.","journal-title":"Blood Adv"},{"key":"1566_CR10","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1007\/s12325-021-01756-0","volume":"38","author":"G Salles","year":"2021","unstructured":"Salles G, Spin P, Liu FF, Garcia J, Kim Y, Hasskarl J. Indirect treatment comparison of Liso-Cel vs. salvage chemotherapy in diffuse large B-cell lymphoma: TRANSCEND vs. SCHOLAR-1. Adv Ther. 2021;38:3266\u201380. https:\/\/doi.org\/10.1007\/s12325-021-01756-0.","journal-title":"Adv Ther"},{"key":"1566_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph191912366","volume":"19","author":"G Choi","year":"2022","unstructured":"Choi G, Shin G, Bae S. Price and prejudice? The value of chimeric antigen receptor (CAR) T-cell therapy. Int J Environ Res Public Health. 2022;19:12366. https:\/\/doi.org\/10.3390\/ijerph191912366.","journal-title":"Int J Environ Res Public Health"},{"key":"1566_CR12","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jval.2024.04.004","volume":"27","author":"K Thavorn","year":"2024","unstructured":"Thavorn K, Thompson ER, Kumar S, Heiskanen A, Agarwal A, Atkins H, et al. Economic evaluations of chimeric antigen receptor T-cell therapies for hematologic and solid malignancies: a systematic review. Value Health. 2024;27:1149\u201373. https:\/\/doi.org\/10.1016\/j.jval.2024.04.004.","journal-title":"Value Health"},{"key":"1566_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/13696998.2023.2290832","volume":"27","author":"OO Oluwole","year":"2024","unstructured":"Oluwole OO, Patel AR, Vadgama S, Smith NJ, Blissett R, Feng C, et al. An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States. J Med Econ. 2024;27:77\u201383. https:\/\/doi.org\/10.1080\/13696998.2023.2290832.","journal-title":"J Med Econ"},{"key":"1566_CR14","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1080\/13696998.2023.2260689","volume":"26","author":"ASL Loftager","year":"2023","unstructured":"Loftager ASL, Dan\u00f8 A, Eklund O, Vadgama S, Hedlof Kanje V, Munk E. Axicabtagene ciloleucel compared to standard of care in Swedish patients with large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial. J Med Econ. 2023;26:1303\u201317. https:\/\/doi.org\/10.1080\/13696998.2023.2260689.","journal-title":"J Med Econ"},{"key":"1566_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.03.005","volume":"27","author":"S Wakase","year":"2021","unstructured":"Wakase S, Teshima T, Zhang J, Ma Q, Fujita T, Yang H, et al. Cost effectiveness analysis of tisagenlecleucel for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma in Japan. Transplant Cell Ther. 2021;27:506.e1\u201310. https:\/\/doi.org\/10.1016\/j.jtct.2021.03.005.","journal-title":"Transplant Cell Ther"},{"key":"1566_CR16","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1080\/13696998.2021.1901721","volume":"24","author":"R Liu","year":"2021","unstructured":"Liu R, Oluwole OO, Diakite I, Botteman MF, Snider JT, Locke FL. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. J Med Econ. 2021;24:458\u201368. https:\/\/doi.org\/10.1080\/13696998.2021.1901721.","journal-title":"J Med Econ"},{"key":"1566_CR17","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.18.02079","volume":"37","author":"JK Lin","year":"2019","unstructured":"Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol. 2019;37:2105\u201319. https:\/\/doi.org\/10.1200\/JCO.18.02079.","journal-title":"J Clin Oncol"},{"key":"1566_CR18","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1080\/13696998.2020.1808981","volume":"23","author":"BP Cher","year":"2020","unstructured":"Cher BP, Gan KY, Aziz MIA, Lin L, Hwang WYK, Poon LM, et al. Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed\/refractory diffuse large B-cell lymphoma from Singapore\u2019s healthcare system perspective. J Med Econ. 2020;23:1321\u20139. https:\/\/doi.org\/10.1080\/13696998.2020.1808981.","journal-title":"J Med Econ"},{"key":"1566_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231168215","volume":"14","author":"N Li","year":"2023","unstructured":"Li N, Lei J, Zhang J, Cai H, Zheng B, Yang T, et al. Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in China and the United States. Ther Adv Hematol. 2023;14:20406207231168215. https:\/\/doi.org\/10.1177\/20406207231168215.","journal-title":"Ther Adv Hematol"},{"key":"1566_CR20","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1007\/s00520-022-07041-2","volume":"30","author":"N Li","year":"2022","unstructured":"Li N, Zheng B, Cai H, Yang T, Hong Y, Liu M, et al. Cost-effectiveness analysis of axicabtagene ciloleucel vs. salvage chemotherapy for relapsed or refractory adult diffuse large B-cell lymphoma in China. Support Care Cancer. 2022;30:6113\u201321. https:\/\/doi.org\/10.1007\/s00520-022-07041-2.","journal-title":"Support Care Cancer"},{"key":"1566_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030538","volume":"14","author":"M Bastos-Oreiro","year":"2022","unstructured":"Bastos-Oreiro M, de Las Heras A, Presa M, Casado MA, Pardo C, Mart\u00edn-Escudero V, et al. Cost-effectiveness analysis of axicabtagene ciloleucel vs. tisagenlecleucel for the management of relapsed\/refractory diffuse large B-cell lymphoma in Spain. Cancers. 2022;14:538. https:\/\/doi.org\/10.3390\/cancers14030538.","journal-title":"Cancers"},{"key":"1566_CR22","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1200\/JCO.22.00478","volume":"41","author":"A Vijenthira","year":"2023","unstructured":"Vijenthira A, Kuruvilla J, Crump M, Jain M, Prica A. Cost-effectiveness analysis of frontline polatuzumab-rituximab, cyclophosphamide, doxorubicin, and prednisone and\/or second-line chimeric antigen receptor T-cell therapy versus standard of care for treatment of patients with intermediate- to high-risk diffuse large B-cell lymphoma. J Clin Oncol. 2023;41:1577\u201389. https:\/\/doi.org\/10.1200\/JCO.22.00478.","journal-title":"J Clin Oncol"},{"key":"1566_CR23","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.clinthera.2021.06.011","volume":"43","author":"CZ Qi","year":"2021","unstructured":"Qi CZ, Bollu V, Yang H, Dalal A, Zhang S, Zhang J. Cost-effectiveness analysis of tisagenlecleucel for the treatment of patients with relapsed or refractory diffuse large B-Cell lymphoma in the United States. Clin Ther. 2021;43:1300-19.e8. https:\/\/doi.org\/10.1016\/j.clinthera.2021.06.011.","journal-title":"Clin Ther"},{"key":"1566_CR24","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/ejh.14095","volume":"111","author":"MS Kurte","year":"2023","unstructured":"Kurte MS, Siefen A-C, Jakobs F, von Tresckow B, Reinhardt HC, Kron F. Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options: experience of the efficiency frontier approach. Eur J Haematol. 2023;111:895\u2013908. https:\/\/doi.org\/10.1111\/ejh.14095.","journal-title":"Eur J Haematol"},{"key":"1566_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/13696998.2021.1922066","volume":"24","author":"XJ Wang","year":"2021","unstructured":"Wang XJ, Wang Y-H, Li SCT, Gkitzia C, Lim ST, Koh LP, et al. Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore\u2019s private insurance payer\u2019s perspective. J Med Econ. 2021;24:637\u201353. https:\/\/doi.org\/10.1080\/13696998.2021.1922066.","journal-title":"J Med Econ"},{"key":"1566_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.45956","volume":"5","author":"JH Choe","year":"2022","unstructured":"Choe JH, Abdel-Azim H, Padula WV, Abou-El-Enein M. Cost-effectiveness of axicabtagene ciloleucel and tisagenlecleucel as second-line or later therapy in relapsed or refractory diffuse large B-cell lymphoma. JAMA Netw Open. 2022;5:e2245956. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.45956.","journal-title":"JAMA Netw Open"},{"key":"1566_CR27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/13696998.2022.2065787","volume":"25","author":"OO Oluwole","year":"2022","unstructured":"Oluwole OO, Liu R, Diakite I, Feng C, Patel A, Nourhussein I, et al. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US. J Med Econ. 2022;25:541\u201351. https:\/\/doi.org\/10.1080\/13696998.2022.2065787.","journal-title":"J Med Econ"},{"key":"1566_CR28","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1007\/s12325-022-02188-0","volume":"39","author":"AK Cummings Joyner","year":"2022","unstructured":"Cummings Joyner AK, Snider JT, Wade SW, Wang S-T, Buessing MG, Johnson S, et al. Cost-effectiveness of chimeric antigen receptor T cell therapy in patients with relapsed or refractory large B cell lymphoma: no impact of site of care. Adv Ther. 2022;39:3560\u201377. https:\/\/doi.org\/10.1007\/s12325-022-02188-0.","journal-title":"Adv Ther"},{"key":"1566_CR29","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s12325-023-02444-x","volume":"40","author":"C Parker","year":"2023","unstructured":"Parker C, Liu FF, Deger KA, Franco-Villalobos C, Proskorovsky I, Keating SJ, et al. Cost-effectiveness of lisocabtagene maraleucel versus axicabtagene ciloleucel and tisagenlecleucel in the third-line or later treatment setting for relapsed or refractory large B-cell lymphoma in the United States. Adv Ther. 2023;40:2355\u201374. https:\/\/doi.org\/10.1007\/s12325-023-02444-x.","journal-title":"Adv Ther"},{"key":"1566_CR30","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1182\/blood.2022016747","volume":"140","author":"SK Thiruvengadam","year":"2022","unstructured":"Thiruvengadam SK, Saumoy M, Schneider Y, Serrao S, Solaimani P, Budde LE, et al. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood. 2022;140:2024\u201336. https:\/\/doi.org\/10.1182\/blood.2022016747.","journal-title":"Blood"},{"key":"1566_CR31","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1007\/s12325-021-01767-x","volume":"38","author":"M Moradi-Lakeh","year":"2021","unstructured":"Moradi-Lakeh M, Yaghoubi M, Seitz P, Javanbakht M, Brock E. Cost-effectiveness of tisagenlecleucel in paediatric acute lymphoblastic leukaemia (pALL) and adult diffuse large B-cell lymphoma (DLBCL) in Switzerland. Adv Ther. 2021;38:3427\u201343. https:\/\/doi.org\/10.1007\/s12325-021-01767-x.","journal-title":"Adv Ther"},{"key":"1566_CR32","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2023.2166375","volume":"11","author":"N Carey","year":"2023","unstructured":"Carey N, Leahy J, Trela-Larsen L, Mc Cullagh L, Barry M. Cost-utility and value of information analysis of tisagenlecleucel for relapsed\/refractory diffuse large B-cell lymphoma in the Irish healthcare setting. J Mark Access Health Policy. 2023;11:2166375. https:\/\/doi.org\/10.1080\/20016689.2023.2166375.","journal-title":"J Mark Access Health Policy"},{"key":"1566_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12962-022-00400-0","volume":"20","author":"F Jakobs","year":"2022","unstructured":"Jakobs F, Jeck J, Ahmadi P, Kron A, Kron F. Health economic analysis of third-line interventions in diffuse large B-cell lymphomas in Germany: applying the efficiency frontier. Cost Eff Resour Alloc. 2022;20:67. https:\/\/doi.org\/10.1186\/s12962-022-00400-0.","journal-title":"Cost Eff Resour Alloc"},{"key":"1566_CR34","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.7326\/M22-2276","volume":"176","author":"AH Kelkar","year":"2023","unstructured":"Kelkar AH, Cliff ERS, Jacobson CA, Abel GA, Dijk SW, Krijkamp EM, et al. Second-line chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma: a cost-effectiveness analysis. Ann Intern Med. 2023;176:1625\u201337. https:\/\/doi.org\/10.7326\/M22-2276.","journal-title":"Ann Intern Med"},{"key":"1566_CR35","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40273-022-01169-z","volume":"40","author":"C Hillis","year":"2022","unstructured":"Hillis C, Vicente C, Ball G. The cost effectiveness of axicabtagene ciloleucel versus best supportive care in the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy in Canada. Pharmacoeconomics. 2022;40:917\u201328. https:\/\/doi.org\/10.1007\/s40273-022-01169-z.","journal-title":"Pharmacoeconomics"},{"key":"1566_CR36","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40258-023-00817-5","volume":"21","author":"W Wu","year":"2023","unstructured":"Wu W, Zhou Y, Wang Y, Keramat SA, Balasooriya NN, Zhao Z, et al. Value for money of CAR-T cell therapy for patients with diffuse large B-cell lymphoma in China: evidence from a cost-effectiveness analysis. Appl Health Econ Health Policy. 2023;21:773\u201383. https:\/\/doi.org\/10.1007\/s40258-023-00817-5.","journal-title":"Appl Health Econ Health Policy"},{"key":"1566_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6890","volume":"368","author":"M Campbell","year":"2020","unstructured":"Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;368:l6890.","journal-title":"BMJ"},{"key":"1566_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1566_CR39","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1017\/S0266462318000636","volume":"34","author":"M Arber","year":"2018","unstructured":"Arber M, Glanville J, Isojarvi J, Baragula E, Edwards M, Shaw A, et al. Which databases should be used to identify studies for systematic reviews of economic evaluations? Int J Technol Assess Health Care. 2018;34:547\u201354. https:\/\/doi.org\/10.1017\/S0266462318000636.","journal-title":"Int J Technol Assess Health Care"},{"key":"1566_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/23814683211061097","volume":"7","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. MDM Policy Pract. 2022;7:23814683211061097.","journal-title":"MDM Policy Pract"},{"key":"1566_CR41","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015."},{"key":"1566_CR42","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12913-022-07595-1","volume":"22","author":"BS Bagepally","year":"2022","unstructured":"Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, Attia J, Thakkinstian A. Meta-analysis of economic evaluation studies: data harmonisation and methodological issues. BMC Health Serv Res. 2022;22:202. https:\/\/doi.org\/10.1186\/s12913-022-07595-1.","journal-title":"BMC Health Serv Res"},{"key":"1566_CR43","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1007\/s12325-024-02971-1","volume":"41","author":"M Ray","year":"2024","unstructured":"Ray M, Castaigne J-G, Zang A, Patel A, Hancock E, Brighton N, et al. A cost-effectiveness analysis of axicabtagene ciloleucel versus tisagenlecleucel in the treatment of diffuse large B-cell lymphoma based on a real-world French registry. Adv Ther. 2024;41:4282\u201398. https:\/\/doi.org\/10.1007\/s12325-024-02971-1.","journal-title":"Adv Ther"},{"key":"1566_CR44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1080\/13696998.2024.2305558","volume":"27","author":"OO Oluwole","year":"2024","unstructured":"Oluwole OO, Ray MD, Davies N, Bradford R, Jones C, Patel AR, et al. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed\/refractory large B-cell lymphoma in the United States: incorporating longer survival results. J Med Econ. 2024;27:230\u20139. https:\/\/doi.org\/10.1080\/13696998.2024.2305558.","journal-title":"J Med Econ"},{"key":"1566_CR45","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.2217\/fon-2023-1114","volume":"20","author":"S Tsutsu\u00e9","year":"2024","unstructured":"Tsutsu\u00e9 S, Makita S, Asou H, Matsuda H, Yamaura R, Taylor TD. Cost-effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan. Future Oncol. 2024;20:1333\u201349. https:\/\/doi.org\/10.2217\/fon-2023-1114.","journal-title":"Future Oncol"},{"key":"1566_CR46","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"key":"1566_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980.","journal-title":"N Engl J Med"},{"key":"1566_CR48","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0.","journal-title":"Lancet"},{"key":"1566_CR49","doi-asserted-by":"publisher","first-page":"S143","DOI":"10.1016\/j.bulcan.2021.07.002","volume":"108","author":"F Broussais","year":"2021","unstructured":"Broussais F, Bay JO, Boissel N, Baruchel A, Arnulf B, Morschhauser F, et al. DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France. Bull Cancer (Paris). 2021;108:S143\u201354. https:\/\/doi.org\/10.1016\/j.bulcan.2021.07.002.","journal-title":"Bull Cancer (Paris)."},{"key":"1566_CR50","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40249-022-01032-5","volume":"11","author":"Z Liu","year":"2022","unstructured":"Liu Z, Li M, Hutton DW, Wagner AL, Yao Y, Zhu W, et al. Impact of the national hepatitis B immunization program in China: a modeling study. Infect Dis Poverty. 2022;11:106. https:\/\/doi.org\/10.1186\/s40249-022-01032-5.","journal-title":"Infect Dis Poverty"},{"key":"1566_CR51","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3111\/13696998.2016.1151432","volume":"19","author":"R Goeree","year":"2016","unstructured":"Goeree R, Villeneuve J, Goeree J, Penrod JR, Orsini L, Tahami Monfared AA. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes. J Med Econ. 2016;19:630\u201344. https:\/\/doi.org\/10.3111\/13696998.2016.1151432.","journal-title":"J Med Econ"},{"key":"1566_CR52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40273-019-00845-x","volume":"38","author":"C Smare","year":"2020","unstructured":"Smare C, Lakhdari K, Doan J, Posnett J, Johal S. Evaluating partitioned survival and Markov decision-analytic modeling approaches for use in cost-effectiveness analysis: estimating and comparing survival outcomes. Pharmacoeconomics. 2020;38:97\u2013108. https:\/\/doi.org\/10.1007\/s40273-019-00845-x.","journal-title":"Pharmacoeconomics"},{"key":"1566_CR53","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/0272989X17697019","volume":"37","author":"N Hawkins","year":"2017","unstructured":"Hawkins N, Grieve R. Extrapolation of survival data in cost-effectiveness analyses: the need for causal clarity. Med Decis Mak. 2017;37:337\u20139. https:\/\/doi.org\/10.1177\/0272989X17697019.","journal-title":"Med Decis Mak"},{"key":"1566_CR54","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","volume":"23","author":"BS Woods","year":"2020","unstructured":"Woods BS, Sideris E, Palmer S, Latimer N, Soares M. Partitioned survival and state transition models for healthcare decision making in oncology: where are we now? Value Health. 2020;23:1613\u201321. https:\/\/doi.org\/10.1016\/j.jval.2020.08.2094.","journal-title":"Value Health"},{"key":"1566_CR55","doi-asserted-by":"publisher","first-page":"A194","DOI":"10.1016\/j.jval.2014.03.1130","volume":"17","author":"D Coyle","year":"2014","unstructured":"Coyle D, Coyle K. PRM74: the inherent bias from using partitioned survival models in economic evaluation. Value Health. 2014;17:A194. https:\/\/doi.org\/10.1016\/j.jval.2014.03.1130.","journal-title":"Value Health"},{"key":"1566_CR56","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473302","volume":"45","author":"IA Nizamuddin","year":"2025","unstructured":"Nizamuddin IA, Ghobadi A. Chimeric antigen receptor T-cell therapy and bispecific antibody use in earlier lines of treatment of large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. Am Soc Clin Oncol Educ Book. 2025;45:e473302. https:\/\/doi.org\/10.1200\/EDBK-25-473302.","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01566-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01566-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01566-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:30:01Z","timestamp":1771421401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01566-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1566"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01566-0","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tien Hoang Tran and Hyung Seok John Kim report no potential conflicts of interest now or over the 3 years prior to submission involving the work under consideration for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study used publicly available data posted in databases such as PubMed and EMBASE. No confidential data or those requiring data use agreements were used for this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Each author contributed equally across all domains of concept and design, acquisition, analysis, or interpretation of data, manuscript drafting, critical review of manuscript, statistical analysis, administrative, technical, or material support, and supervision.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}